Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts are broadly positive on Halozyme Therapeutics, with the stock receiving an average rating of “Moderate Buy” from 13 firms and a consensus price target of $81.60. The breakdown includes eight buy ratings, four hold ratings, and one sell rating.
• Recent financial results were strong, as the company reported quarterly EPS of $1.60, topping estimates, and revenue of $376.71 million, also above expectations. Revenue rose 42.2% year over year, and Halozyme reiterated FY 2026 EPS guidance of $7.75 to $8.25.
• Insiders have been selling shares, including CEO Helen Torley and Director Bernadette Connaughton, with 93,250 shares sold over the past 90 days worth about $6.3 million. Despite that, institutional ownership remains high at 97.79%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $81.60.

A number of analysts have commented on the stock. Wall Street Zen raised shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, May 16th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 12th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a "hold (c)" rating to a "buy (b-)" rating in a research report on Tuesday, May 12th.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25. Following the transaction, the director directly owned 43,669 shares in the company, valued at approximately $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 93,250 shares of company stock worth $6,299,746. 2.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC boosted its stake in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares in the last quarter. Clearstead Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 265 shares in the last quarter. Harbour Investments Inc. boosted its stake in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 372 shares in the last quarter. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $70,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $68.55 on Monday. Halozyme Therapeutics has a twelve month low of $51.06 and a twelve month high of $82.22. The company has a 50 day moving average of $68.02 and a 200-day moving average of $68.64. The stock has a market capitalization of $8.13 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 0.28 and a beta of 0.88. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analysts' expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm's revenue was up 42.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts anticipate that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.